A Systematic Literature Review of the Economic Evaluations of Treatments for Patients with Chronic Myeloid Leukemia
Authors:
- 30 September 2022
- journal article
- review article
- Published by Springer Nature in PharmacoEconomics
- Vol. 40 (12) , 1159-1186
Abstract
Background and Objectives The management of chronic myeloid leukemia is associated with an extensive economic burden, and as novel interventions are being tested in this disease, understanding the comparative effectiveness is of interest. Findings and conclusions of this important issue continue to evolve with improvements in clinical research and economic understanding. This systematic literature review aims to conduct a comprehensive assessment of economic evaluations in chronic phase chronic myeloid leukemia. Methods Embase®, MEDLINE®, and the National Health Service Economic Evaluation Database were searched on 4 July, 2022 to identify economic evaluations of chronic myeloid leukemia. Health technology assessment websites and key conference proceedings were also searched. Economic evaluations comparing treatment options in adult patients with chronic phase chronic myeloid leukemia were included. The quality of the studies were assessed using Drummond’s checklists. Results The search retrieved 47 studies and 16 health technology assessments that fulfilled the eligibility criteria. Most were cost-utility analyses (23 studies and 11 health technology assessments) and were from the USA (n = 15) and China (n = 7). Twenty-seven studies and six health technology assessments included only patients with chronic phase chronic myeloid leukemia. Most models had a Markov structure, a 1 year to lifetime time horizon, and a 1-month cycle length. Commonly assessed treatments were various tyrosine kinase inhibitors (imatinib, nilotinib, dasatinib, bosutinib, and ponatinib) and other interventions such as interferon-α, hydroxyurea, and allogeneic stem cell transplant. Conclusions In patients with newly diagnosed chronic myeloid leukemia, imatinib regimens were cost effective, mostly owing to the availability of generics. Nilotinib and dasatinib were generally cost effective as second-line agents for patients who were resistant or intolerant to imatinib. Though progress has been made to better characterize the cost effectiveness of first-line and second-line chronic myeloid leukemia therapies, the paucity of published cost-effectiveness studies of third-line treatments increases the uncertainty associated with economic evaluations of later lines of therapy.Keywords
Funding Information
- Novartis Services Inc
This publication has 59 references indexed in Scilit:
- Cost-effectiveness of dasatinib versus high-dose imatinib in patients with Chronic Myeloid Leukemia (CML), resistant to standard dose imatinib – a Swedish model applicationActa Oncologica, 2010
- A Multinational Study of Health State Preference Values Associated with Chronic Myelogenous LeukemiaValue in Health, 2010
- Cost-Effectiveness Study Comparing Imatinib with Interferon-α for Patients with Newly Diagnosed Chronic-Phase (CP) Chronic Myeloid Leukemia (CML) from the Chinese Public Health-Care System Perspective (CPHSP)Value in Health, 2009
- PCN124 COST-UTILITY ANALYSIS OF DASATINIB IN PATIENTS WITH IMATINIB-RESISTANT CHRONIC MYELOID LEUKEMIA (CML) ON CHRONIC (CP), ACCELERATED (AP) AND BLAST (BP) PHASES IN BRAZILValue in Health, 2009
- PCN14 THE COST AND COST EFFECTIVENESS OF DASATINIB (SPRYCEL) 100 MG THERAPY FOR THE MANAGEMENT OF IMATINIB RESISTANT AND INTOLERANT PATIENTS IN CHRONIC PHASE WITH CHRONIC MYELOID LEUKEMIA (CML) IN MÉXICOValue in Health, 2009
- Updated Estimates of Survival and Cost Effectiveness for Imatinib versus Interferon-?? Plus Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid LeukaemiaPharmacoEconomics, 2008
- Cost utility of allogeneic stem cell transplantation with matched unrelated donor versus treatment with imatinib for adult patients with newly diagnosed chronic myeloid leukaemiaJournal of Medical Economics, 2008
- Staging of chronic myeloid leukemia in the imatinib eraCancer, 2006
- Cost Effectiveness of Imatinib Compared with Interferon-?? or Hydroxycarbamide for First-Line Treatment of Chronic Myeloid LeukaemiaPharmacoEconomics, 2005
- Cytarabine Added to Interferon Improves the Cost-Effectiveness of Initial Therapy for Patients with Early Chronic Phase Chronic Myelogenous LeukemiaLeukemia & Lymphoma, 2001